Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL.
Slomovitz BM, et al.
J Clin Oncol. 2015 Mar 10;33(8):930-6. doi: 10.1200/JCO.2014.58.3401. Epub 2015 Jan 26.
J Clin Oncol. 2015.
PMID: 25624430
Free PMC article.
Clinical Trial.
Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. ...Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole. CONCLUSION: …
Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 we …